How Much Does BPC-157 Cost? (2026 Price Guide)

In 2026, research-grade BPC-157 typically costs about $38–$95 per 5 mg vial, or roughly $5–$8 per milligram, from vendors that publish third-party purity testing. A 10 mg vial generally runs $70–$120. BPC-157 is not FDA-approved, and pricing varies widely by purity verification, vial size, and source.

BPC-157 cost at a glance

• Typical 5 mg vial: ~$38–$95 (research market, 2026) [VERIFY: vendor-survey range]
• Typical 10 mg vial: ~$70–$120 [VERIFY: vendor-survey range]
• Price per mg: ~$5–$8 from documented vendors; under ~$3/mg is a quality red flag [VERIFY: vendor-survey range]
• Estimated monthly cost (at a commonly cited 500 mcg/day, from a 10 mg vial): ~$25–$50 [VERIFY: derived estimate]
• Biggest cost driver: third-party purity verification (HPLC, mass spec), not vial size
• FDA status: not approved for human use; placed in Category 2 on the 503A bulk-substances review list in 2023; under Pharmacy Compounding Advisory Committee review July 23–24, 2026

How much does BPC-157 cost in 2026?

Across the 2026 research-peptide market, BPC-157 is most commonly listed at roughly $38–$95 for a 5 mg vial and $70–$120 for a 10 mg vial, which works out to about $5–$8 per milligram from vendors that publish batch-level testing [VERIFY: figures aggregated from 2026 vendor listings, not a single primary source]. These are catalog prices for material sold "for research use only," not the price of an FDA-approved medicine — BPC-157 has no approved human formulation, so there is no insurance code, no pharmacy copay, and no manufacturer list price to anchor against.

Because the market is unregulated at the consumer level, the spread is wide. The same nominal "5 mg of BPC-157" can be priced 2–3x apart between two vendors, and the cheaper option is not always the better value once purity and dose accuracy are accounted for. Price alone tells you very little about what is actually in the vial.

The numbers in this guide are observed market ranges, not clinical guidance. Consult your healthcare provider before considering any peptide protocol, and see our BPC-157 complete guide for the underlying research context.

What drives the price of BPC-157?

Four factors explain most of the price differences you will see:

1. Purity verification depth. Independent third-party analysis — high-performance liquid chromatography (HPLC) for purity, mass spectrometry to confirm the molecule, and endotoxin/sterility testing — adds real, fixed cost per batch [VERIFY: per-batch testing cost figures from vendor disclosures]. A vendor that pays for full testing and publishes a current Certificate of Analysis (COA) carries cost a "skip-the-testing" seller does not.
2. Vial size and per-mg math. A 10 mg vial usually costs only 30–60% more than a 5 mg vial but contains twice the peptide, so the per-milligram price is lower. Buying by total milligrams, not by sticker price, is how you compare honestly.
3. Synthesis quality and yield. BPC-157 is a 15-amino-acid synthetic peptide; solid-phase peptide synthesis with proper purification costs more than crude product, and that shows up in price.
4. Source type. Research-chemical catalogs, longevity/wellness clinics, and compounding pharmacies price very differently (see the next section).

A suspiciously low price — well under ~$3/mg — most often signals unverified purity, an overstated quantity, or under-filled vials, not a genuine bargain. Use a peptide price-per-mg calculator and a vendor quality checklist before comparing two listings.

How does BPC-157 pricing differ by source: research vendors vs. clinics vs. compounding pharmacies?

There are three broad channels, and they are not interchangeable:

• Research-chemical vendors (the "$38–$95 per 5 mg" market) sell material labeled for research/laboratory use only — not for human consumption. This is the cheapest per-milligram channel and the one most price guides describe, but it sits entirely outside the medical system, with no prescriber, no pharmacist oversight, and highly variable quality control.
• Longevity/wellness clinics bundle BPC-157 into paid programs that may include consultation, supplies, and follow-up. Headline program pricing is higher than a raw vial because you are paying for services, not just peptide.
• Compounding pharmacies are the only channel tied to a prescription and pharmacist oversight — but their ability to compound BPC-157 is exactly what is in regulatory flux in 2026 (next section). Availability and price here depend on the FDA's pending decisions.

The lowest number you find online is almost always the research-vendor channel, and the cost difference between channels largely reflects the absence (or presence) of medical oversight. A licensed healthcare provider can help you weigh those tradeoffs.

What is the real monthly cost of a BPC-157 protocol?

Monthly cost depends entirely on dose and cycle length, which should be set with a clinician rather than copied from a forum. Research and community discussions commonly cite 250–500 mcg per injection, once or twice daily, for short cycles — not a recommendation here, just the range you will encounter.

Using simple arithmetic on a 10 mg vial:

• At 500 mcg/day, a 10 mg vial provides ~20 days, so a 30-day month needs ~1.5 vials. At ~$25–$50 per 10 mg vial of value, that is roughly $40–$75/month in peptide alone [VERIFY: derived estimate, depends on per-vial price].
• At 250 mcg/day, the same vial stretches ~40 days, lowering monthly peptide cost accordingly.

These figures cover the peptide only. A realistic budget also includes bacteriostatic water, insulin syringes, alcohol swabs, and sharps disposal, plus — in any responsible scenario — the cost of a consultation and any baseline lab work your provider recommends. Dosing and cycle length should be personalized with a provider; this section is illustrative math, not a protocol. Consult your healthcare provider before starting any peptide protocol.

Why is BPC-157 not just available at a normal pharmacy (and how does that affect price)?

The single biggest reason BPC-157 pricing is so messy is its regulatory status. BPC-157 is not FDA-approved for any use, and in 2023 the FDA placed it in Category 2 of its review of bulk drug substances nominated for compounding under section 503A — substances for which the agency identified potential significant safety risks pending further evaluation, and which were therefore not eligible for the interim compounding policy (U.S. Food and Drug Administration, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks).

In 2026 the picture is shifting. The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to discuss BPC-157 (reviewing BPC-157 free base and BPC-157 acetate as separate nominations) along with several other peptides, for possible inclusion on the 503A bulks list (U.S. FDA, July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee). Reporting and regulatory-tracking sources indicate the agency removed BPC-157 from the explicit Category 2 prohibition earlier in 2026 after nominators' withdrawals, moving it into a transitional, under-review state — but removal from Category 2 is not FDA approval and does not by itself add BPC-157 to the positive bulks list [VERIFY: April 2026 Category 2 removal — confirm against the FDA bulk-substances page text before publishing].

Why this matters for price: because no FDA-approved product exists and legitimate pharmacy compounding has been constrained, most consumer-facing supply has flowed through the unregulated research-chemical market, where prices are low but quality and accuracy are unverified. If the July 2026 PCAC review ultimately expands compliant compounding access, the pricing and oversight landscape could change. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Is cheaper BPC-157 worth it? What the research actually shows

It is tempting to chase the lowest price, but the evidence base is the reason quality verification matters more than saving a few dollars. Most BPC-157 research is preclinical (animal and cell-culture) — not large human clinical trials. In a rat Achilles-tendon model combined with cell-culture work, BPC-157 promoted tendon healing through tendon outgrowth, improved cell survival under oxidative stress, and increased fibroblast migration (Chang et al., 2011, Journal of Applied Physiology). Follow-up work reported that BPC-157 up-regulated the growth-hormone receptor in tendon fibroblasts at both mRNA and protein levels, a proposed mechanism for its effect on connective tissue (Chang et al., 2014, Molecules). Review literature describes BPC-157 as stable in human gastric juice with no reported toxicity in early inflammatory-bowel-disease trials of related formulations (Sikiric et al., 2020, Gut and Liver; Sikiric et al., 2006, Current Pharmaceutical Design).

Research in animal models suggests BPC-157 may support tissue repair; robust human efficacy and long-term safety data are limited. That uncertainty is exactly why paying for verified purity — rather than buying the cheapest unverified vial — is the cautious approach. Consult your healthcare provider before starting any peptide protocol.

How can you compare BPC-157 prices fairly?

To avoid overpaying or buying low-quality material:

1. Convert everything to price per milligram. A $50 5 mg vial ($10/mg) is more expensive than an $85 10 mg vial ($8.50/mg).
2. Demand a current COA. A real, recent third-party COA (HPLC purity + mass-spec identity) is non-negotiable; "tested" with no document is not testing.
3. Reject prices that are too good. Far-below-market pricing usually means a cost was cut somewhere you cannot see.
4. Account for total protocol cost, including supplies and provider consultation — not just the vial.
5. Re-check legal status, which is actively changing in 2026.

For a deeper framework, see our guide to spotting a quality peptide vendor.

Frequently asked questions

Q: How much does a single 5 mg vial of BPC-157 cost in 2026? A: In the 2026 research-peptide market, a 5 mg vial of BPC-157 is most commonly listed around $38–$95, depending on the vendor's purity verification and source [VERIFY: vendor-survey range]. That works out to roughly $7.60–$19 per milligram for a 5 mg vial, though 10 mg vials usually lower the per-mg cost. These are catalog prices for "research use only" material, not an FDA-approved medication, so there is no insurance coverage or standardized pricing. Always convert to price-per-mg before comparing, and consult your healthcare provider before considering any protocol.

Q: Why is BPC-157 so cheap compared to prescription medications? A: Most consumer-facing BPC-157 is sold through the unregulated research-chemical channel rather than as an FDA-approved drug, so it carries none of the costs of clinical trials, FDA approval, or pharmacy distribution. That low price reflects a lack of oversight, not a bargain: purity, identity, and fill quantity are frequently unverified. Prices well under roughly $3 per milligram are widely treated as a red flag for unverified purity or overstated quantity. Verified third-party testing is what you are really paying for.

Q: What is a fair price per milligram for BPC-157? A: From a vendor that publishes a current third-party Certificate of Analysis, roughly $5–$8 per milligram is a commonly observed 2026 range [VERIFY: vendor-survey range]. Below about $3/mg is generally considered a warning sign — the likely explanation is unverified purity, under-filled vials, or overstated quantity rather than genuine efficiency. The cost of HPLC and mass-spectrometry testing is largely fixed per batch, so legitimate testing sets a practical price floor that bargain listings tend to fall below.

Q: How much does a full BPC-157 protocol cost per month? A: Monthly cost depends on dose and cycle, which should be set with a provider, not copied online. Using a commonly cited 500 mcg/day on a 10 mg vial, the peptide itself runs roughly $40–$75 per month [VERIFY: derived estimate]; a 250 mcg/day approach costs less. Add bacteriostatic water, syringes, swabs, sharps disposal, and any consultation or lab fees your clinician recommends for a realistic total. Consult your healthcare provider before starting any peptide protocol.

Q: Is BPC-157 covered by insurance? A: No. BPC-157 is not FDA-approved for any use, so it has no insurance reimbursement, no copay, and no standardized pharmacy price. Any BPC-157 you encounter is sold either as "research use only" material or through cash-pay clinic programs and (where regulations allow) compounding. Because there is no approved product, all costs are out of pocket. This is one reason its pricing is so variable across vendors and channels.

Q: Will the July 2026 FDA advisory committee meeting change BPC-157's price or availability? A: Possibly. The Pharmacy Compounding Advisory Committee is scheduled to discuss BPC-157 on July 23–24, 2026 for potential inclusion on the 503A bulks list (U.S. FDA). If compliant pharmacy compounding access expands, the oversight and pricing landscape could shift toward prescription-based access. However, an advisory-committee discussion is not approval, and any outcome would not make BPC-157 an FDA-approved drug. Legal status varies by jurisdiction; consult a lawyer for binding advice.

Q: Does a higher price mean BPC-157 is more effective? A: Price does not measure efficacy. A higher price may reflect better third-party purity testing, sterility verification, and accurate fill — all of which matter for safety and consistency — but it does not change the underlying evidence. Most BPC-157 research remains preclinical (animal and cell-culture); research in animal models suggests it may support tissue repair, while robust human efficacy data are limited. Pay for verified quality, not for implied benefit, and consult your healthcare provider.

References

1. Chang C-H, Tsai W-C, Lin M-S, Hsu Y-H, Pang J-HS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology. 2011;110(3):774–780. https://journals.physiology.org/doi/full/10.1152/japplphysiol.00945.2010
2. Chang C-H, Tsai W-C, Hsu Y-H, Pang J-HS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066–19077. PMC6271067. https://pmc.ncbi.nlm.nih.gov/articles/PMC6271067/ · PubMed: https://pubmed.ncbi.nlm.nih.gov/25415472/
3. Sikiric P, Rucman R, Turkovic B, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and Liver. 2020;14(2):153–167. PMC7096228. https://pmc.ncbi.nlm.nih.gov/articles/PMC7096228/
4. Sikiric P, Seiwerth S, Brcic L, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL 14736, Pliva, Croatia). Current Pharmaceutical Design. 2006;12(23):2807–2813. PubMed: https://pubmed.ncbi.nlm.nih.gov/17186181/
5. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (Category 2, section 503A). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
6. U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
7. U.S. Food and Drug Administration. Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/interim-policy-compounding-using-bulk-drug-substances-under-section-503a-federal-food-drug-and